Clinical trial
A Phase 1 Study to Evaluate the Safety of KLN-1010, a Novel, In Vivo Gene Therapy to Generate Anti-B Cell Maturation Antigen (Anti-BCMA) Chimeric Antigen Receptor-T Cells (CAR-T) in Patients With Relapsed and Refractory Multiple Myeloma
NCT07075185 is registered in ClinicalTrials.gov with Kelonia Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Study to Evaluate the Safety of KLN-1010, a Novel, In Vivo Gene Therapy to Generate Anti-B Cell Maturation Antigen (Anti-BCMA) Chimeric Antigen Receptor-T Cells (CAR-T) in Patients With Relapsed and Refractory Multiple Myeloma
- Lead sponsor
- Kelonia Therapeutics, Inc.
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- July 16, 2025
- Completion date
- May 31, 2042
- Enrollment
- 70 (estimated)
- Sites
- 11
Conditions
As the registry lists them; a condition with its own page is linked.
blood protein disorders, gene therapy, hematologic disease and disorders, hemostatic disorders, immune system disease, immunoproliferative disorders, lymphoproliferative disorders, multiple myeloma in relapse, multiple myeloma progression, myeloma multiple, neoplasm, neoplasms by histologic type, paraproteinemias, vascular disorder